We are excited to share our article on AAV3B Neutralising antibodies and perspectives for increasing treatable population
Vivet Therapeutics is proud to share its recently published article in GeneTherapy entitled Prevalence of adeno-associated virus type 3B neutralizing antibodies in cohorts of healthy donors and Wilson’s disease adults, Celine Bouquet, Blanche Tamarit, Gloria Gonzalez-Aseguinolaza et al.; Gene Therapy (2026) In combination with our VTX-PID, we have generated new insights into anti-AAV3B neutralizing antibodies to expand […]
Lexeo Therapeutics enters into an option agreement for an exclusive license to VTX-PID
Vivet Therapeutics is proud to announce that Lexeo Therapeutics has entered into an option agreement to secure an exclusive license to VTX-PID, our proprietary IgG-degrading enzyme designed to help overcome AAV immunity, notably in naturally immunized patients whose antibodies currently prevent access to game-changing treatments. This collaboration reflects a shared ambition: making gene therapy accessible […]
VTX-802: an investigational gene therapy for PFIC2
A single-dose AAV gene therapy designed to restore the bile transporter missing in progressive familial intrahepatic cholestasis type 2; and what a new preclinical study showed. THE DISEASE Why PFIC2 is hard to treat PFIC2 is a rare, inherited liver disease, about 1 in 100,000 people, caused by mutations in ABCB11, the gene for the bile […]
We are excited to share our paper on VTX- PID in Frontiers In Immunology 2026
VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study Breaking barriers in AAV gene therapy : The NAb challenge has a solution for some patients For too long, we’ve accepted that 30–60% of gene therapy–naïve patients are […]
Vivet Therapeutics to present at ASGCT in Boston
Paris, 6th May 2026 – At the Annual Congress of the American Society of Gene & Cell Therapy (ASGCT), Vivet Therapeutics will present translational modeling data supporting the ability of its proprietary VTX-PID imlifidase formulation to enable AAV gene therapy in NAb-positive subjects : “Modeling of VTX-PID-driven AAV3B Neutralizing Antibody Depletion Expands Treatable Populations Across […]
Vivet Therapeutics to present at ASGCT
Paris, 6th May 2026 – At the Annual Congress of the American Society of Gene & Cell Therapy (ASGCT), Vivet Therapeutics will present translational modeling data supporting the ability of its proprietary VTX-PID imlifidase formulation to enable AAV gene therapy in NAb-positive subjects : “Modeling of VTX-PID-driven AAV3B Neutralizing Antibody Depletion Expands Treatable Populations Across […]
Vivet Therapeutics Presents Breakthrough Data on AAV Neutralizing Antibody Depletion at ESGCT 2025
Sevilla, October 2025 – At the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Vivet Therapeutics shared new clinical data with its VTX-PID proprietary imlifidase formulation, highlighting the effective reduction of neutralizing antibodies (NAbs) against AAV3B in healthy volunteers. Key Findings: Vivet Therapeutics remains committed to advancing innovative therapies and […]
Join us at ESGCT 2025 in Sevilla
Join us at ESGCT 2025 in Sevilla for an important presentation by Jean-Philippe Combal from Vivet Therapeutics on October 9th at 10:00am CET during the session entitled Immune responses to gene therapy. https://lnkd.in/enSxNwzFLearn how VTX-PID (imlifidase) enables optimal depletion of anti-AAV3B neutralizing antibodies in human subjects, expanding eligibility for future systemic AAV-based gene therapies through innovative dose-ranging and […]
Our Pilot study of Cu64 data in Heterozygous Wilson’s Disease patients
We are excited to share our paper on Pilot clinical study showing abnormal copper metabolism in healthy Wilson disease heterozygote subjects, accepted to CTSJournal. See it here : https://lnkd.in/e-rzZnXp #ASCPTJournalFamily – Wilson Disease Association 64Cu has been used for decades to study WD, however clear data are lacking to document the rate of fecal elimination […]
Vivet Therapeutics to Present Key Findings on its Gene Therapy Program forCerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
Paris, France, November 14, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotechcompany developing novel and long-lasting gene therapies for rare inherited liver metabolicdisorders, today announces that it will be presenting key pre-clinical findings for VTX-806, itsgene therapy program for the treatment of Cerebrotendinous Xanthomatosis (CTX), at TheLiver Meeting presented by the American Association for […]